Skip to main content

Treace Medical Concepts, Inc.

corporate_fare Company Profile

Treace Medical Concepts, Inc.

TMCI·NASDAQ·Life Sciences·CIK 0001630627

Treace Medical Concepts, Inc. is a medical technology company focused on improving surgical treatment for bunion and related midfoot deformities. The company has developed and patented the Lapiplasty® 3D Bunion Correction® System, which includes instruments, implants, and surgical methods designed to correct bunion deformities in three dimensions and stabilize the unstable joint that causes bunions. This system addresses the root cause of bunions, which affect an estimated 67 million Americans, with approximately 1.1 million annual surgical candidates. To further support surgeons and patients, Treace Medical Concepts offers additional systems, including the Adductoplasty® Midfoot Correction System for midfoot correction, the Nanoplasty® 3D Minimally Invasive Bunion Correction System and the Percuplasty™ Percutaneous 3D Bunion Correction® System for minimally invasive osteotomy procedures, and the SpeedMTP® System for great toe fusions. The company is also expanding its SpeedPlate® Rapid Compression Implant platform and provides digital solutions like the IntelliGuide® patient-specific, pre-op planning and cut guide technology. Treace Medical Concepts markets and sells its products in the United States primarily through a direct employee sales force, supplemented by independent sales agencies. These efforts target approximately 8,000 surgical podiatrists and 2,600 orthopedic surgeons specializing in foot and ankle in the United States. The company invests in training and educating physicians on the safe and effective use of its systems. It also runs a direct-to-patient outreach program to educate patients on the Lapiplasty System and other products, including a "Find a Doctor" tool on its website to help patients locate trained surgeons.

Treace Medical Concepts, Inc. (NASDAQ:TMCI) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 21 items for TMCI at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Treace Medical Reports Q4 Revenue Decline, Withholds 2026 Guidance Amid Headwinds

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$212.69M
Net Income
-$59M
Diluted EPS
-$0.93
Op. Cash Flow
-$15.97M
Free Cash Flow
-$29.49M
Gross Profit
$169.75M
Operating Income
-$54.15M
Cash & Equivalents
$10.71M
Total Debt
$57.33M
Debt / Equity
0.66×
Net Margin
-27.7%
Shares Outstanding
63.27M sh
Source: 10-K · filed 2026-02-27 · accession 0001193125-26-079167
$4.31
52-week range · as of 2026-11-06 $1.17 – $6.55
Market cap
$282.56M
Volume
232.8K (0.8× avg)
3-mo avg 291K
Live data · 2026-11-22 12:07 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed TMCI - Filings & News (Page 2)

TMCI
Jan 13, 2026, 8:54 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.71
Real-time Price: $4.31 info
Change: +$1.60 (+59%) info
Market Cap: $282.562M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets